First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial.

Nat Cancer · 2026 · PMC13309285 · PMID 42259988

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a possible trendno p-value reported

DoR and PFS were also not clearly associated with central HER2 status, although a possible trend was observed for longer DoR and PFS in HER2 IHC 1+ versus 0 absent membrane staining and ultralow groups.

also in 1,410 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.